FDA授予DSG3-CAART治疗寻常型天疱疮的孤儿药资格

2020-01-30 Allan MedSci原创

Cabaletta Bio是一家临床阶段的生物技术公司,今日宣布,美国FDA已授予候选药物DSG3-CAART孤儿药物资格,用于治疗寻常型天疱疮(PV)。

Cabaletta Bio是一家临床阶段的生物技术公司,今日宣布,美国FDA已授予候选药物DSG3-CAART孤儿药物资格,用于治疗寻常型天疱疮(PV)。寻常型天疱疮是一种罕见的、可能致命的慢性自身免疫性疾病,其特征是粘膜细胞之间的粘附力丧失,导致广泛的损伤。表现为皮肤、口唇、生殖器及其他黏膜上大小不一的水疱。多发于中老年人群,男性和女性罹患此病的几率相同。

Cabaletta首席医学官David Chang称:对于寻常型天疱疮患者,尽管有治疗选择,但迫切需要更有效、更持久的疗法,以提供可靠、全面、持续的疾病缓解。孤儿药物资格是对DSG3-CAART的重要认可


原始出处:

https://www.firstwordpharma.com/node/1696969?tsid=4

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1736302, encodeId=8bb61e36302ca, content=<a href='/topic/show?id=e745466e93c' target=_blank style='color:#2F92EE;'>#寻常型天疱疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46679, encryptionId=e745466e93c, topicName=寻常型天疱疮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024034108725, createdName=paperyu, createdTime=Thu Feb 27 03:21:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079600, encodeId=801820e9600ca, content=<a href='/topic/show?id=b817466e8c2' target=_blank style='color:#2F92EE;'>#寻常型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46678, encryptionId=b817466e8c2, topicName=寻常型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sun Dec 20 07:21:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063791, encodeId=f9a42063e91de, content=<a href='/topic/show?id=a48d6284cb' target=_blank style='color:#2F92EE;'>#DSG3-CAART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6284, encryptionId=a48d6284cb, topicName=DSG3-CAART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Apr 23 18:21:00 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357379, encodeId=ce9c135e37922, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479621, encodeId=9e1f14e962170, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534005, encodeId=e4f41534005ae, content=<a href='/topic/show?id=238c3942eb' target=_blank style='color:#2F92EE;'>#CAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3942, encryptionId=238c3942eb, topicName=CAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad6312510186, createdName=huangdf, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1736302, encodeId=8bb61e36302ca, content=<a href='/topic/show?id=e745466e93c' target=_blank style='color:#2F92EE;'>#寻常型天疱疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46679, encryptionId=e745466e93c, topicName=寻常型天疱疮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024034108725, createdName=paperyu, createdTime=Thu Feb 27 03:21:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079600, encodeId=801820e9600ca, content=<a href='/topic/show?id=b817466e8c2' target=_blank style='color:#2F92EE;'>#寻常型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46678, encryptionId=b817466e8c2, topicName=寻常型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sun Dec 20 07:21:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063791, encodeId=f9a42063e91de, content=<a href='/topic/show?id=a48d6284cb' target=_blank style='color:#2F92EE;'>#DSG3-CAART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6284, encryptionId=a48d6284cb, topicName=DSG3-CAART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Apr 23 18:21:00 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357379, encodeId=ce9c135e37922, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479621, encodeId=9e1f14e962170, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534005, encodeId=e4f41534005ae, content=<a href='/topic/show?id=238c3942eb' target=_blank style='color:#2F92EE;'>#CAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3942, encryptionId=238c3942eb, topicName=CAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad6312510186, createdName=huangdf, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
    2020-12-20 cenghis
  3. [GetPortalCommentsPageByObjectIdResponse(id=1736302, encodeId=8bb61e36302ca, content=<a href='/topic/show?id=e745466e93c' target=_blank style='color:#2F92EE;'>#寻常型天疱疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46679, encryptionId=e745466e93c, topicName=寻常型天疱疮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024034108725, createdName=paperyu, createdTime=Thu Feb 27 03:21:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079600, encodeId=801820e9600ca, content=<a href='/topic/show?id=b817466e8c2' target=_blank style='color:#2F92EE;'>#寻常型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46678, encryptionId=b817466e8c2, topicName=寻常型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sun Dec 20 07:21:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063791, encodeId=f9a42063e91de, content=<a href='/topic/show?id=a48d6284cb' target=_blank style='color:#2F92EE;'>#DSG3-CAART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6284, encryptionId=a48d6284cb, topicName=DSG3-CAART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Apr 23 18:21:00 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357379, encodeId=ce9c135e37922, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479621, encodeId=9e1f14e962170, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534005, encodeId=e4f41534005ae, content=<a href='/topic/show?id=238c3942eb' target=_blank style='color:#2F92EE;'>#CAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3942, encryptionId=238c3942eb, topicName=CAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad6312510186, createdName=huangdf, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1736302, encodeId=8bb61e36302ca, content=<a href='/topic/show?id=e745466e93c' target=_blank style='color:#2F92EE;'>#寻常型天疱疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46679, encryptionId=e745466e93c, topicName=寻常型天疱疮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024034108725, createdName=paperyu, createdTime=Thu Feb 27 03:21:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079600, encodeId=801820e9600ca, content=<a href='/topic/show?id=b817466e8c2' target=_blank style='color:#2F92EE;'>#寻常型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46678, encryptionId=b817466e8c2, topicName=寻常型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sun Dec 20 07:21:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063791, encodeId=f9a42063e91de, content=<a href='/topic/show?id=a48d6284cb' target=_blank style='color:#2F92EE;'>#DSG3-CAART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6284, encryptionId=a48d6284cb, topicName=DSG3-CAART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Apr 23 18:21:00 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357379, encodeId=ce9c135e37922, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479621, encodeId=9e1f14e962170, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534005, encodeId=e4f41534005ae, content=<a href='/topic/show?id=238c3942eb' target=_blank style='color:#2F92EE;'>#CAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3942, encryptionId=238c3942eb, topicName=CAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad6312510186, createdName=huangdf, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
    2020-02-01 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1736302, encodeId=8bb61e36302ca, content=<a href='/topic/show?id=e745466e93c' target=_blank style='color:#2F92EE;'>#寻常型天疱疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46679, encryptionId=e745466e93c, topicName=寻常型天疱疮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024034108725, createdName=paperyu, createdTime=Thu Feb 27 03:21:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079600, encodeId=801820e9600ca, content=<a href='/topic/show?id=b817466e8c2' target=_blank style='color:#2F92EE;'>#寻常型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46678, encryptionId=b817466e8c2, topicName=寻常型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sun Dec 20 07:21:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063791, encodeId=f9a42063e91de, content=<a href='/topic/show?id=a48d6284cb' target=_blank style='color:#2F92EE;'>#DSG3-CAART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6284, encryptionId=a48d6284cb, topicName=DSG3-CAART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Apr 23 18:21:00 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357379, encodeId=ce9c135e37922, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479621, encodeId=9e1f14e962170, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534005, encodeId=e4f41534005ae, content=<a href='/topic/show?id=238c3942eb' target=_blank style='color:#2F92EE;'>#CAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3942, encryptionId=238c3942eb, topicName=CAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad6312510186, createdName=huangdf, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1736302, encodeId=8bb61e36302ca, content=<a href='/topic/show?id=e745466e93c' target=_blank style='color:#2F92EE;'>#寻常型天疱疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46679, encryptionId=e745466e93c, topicName=寻常型天疱疮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024034108725, createdName=paperyu, createdTime=Thu Feb 27 03:21:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079600, encodeId=801820e9600ca, content=<a href='/topic/show?id=b817466e8c2' target=_blank style='color:#2F92EE;'>#寻常型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46678, encryptionId=b817466e8c2, topicName=寻常型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sun Dec 20 07:21:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063791, encodeId=f9a42063e91de, content=<a href='/topic/show?id=a48d6284cb' target=_blank style='color:#2F92EE;'>#DSG3-CAART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6284, encryptionId=a48d6284cb, topicName=DSG3-CAART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Apr 23 18:21:00 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357379, encodeId=ce9c135e37922, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479621, encodeId=9e1f14e962170, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534005, encodeId=e4f41534005ae, content=<a href='/topic/show?id=238c3942eb' target=_blank style='color:#2F92EE;'>#CAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3942, encryptionId=238c3942eb, topicName=CAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad6312510186, createdName=huangdf, createdTime=Sat Feb 01 10:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
    2020-02-01 huangdf